Gufic BioSciences Ltd (GUFICBIO) is currently trading at 435.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gufic Biosciences Limited is a research‑based pharmaceutical company and one of India’s largest manufacturers of lyophilized injections, operating multiple WHO/EU/ANVISA/MHRA/USFDA‑standard facilities across Navsari, Belgaum and Indore, with domestic branded segments, CMO services, API manufacturing and an expanding international registration footprint across regulated and semi‑regulated markets. Indore commissioning materially increases global injectable capacity and is being validated via a phased, compliance‑first approach; management expects Indore to be EBITDA breakeven at ~30% utilization and to unlock export volumes that will de‑bottleneck Navsari and lift regulated‑market sales, while they deliberately manage scaling to preserve audit readiness and quality. Gufic is shifting international strategy from distributor‑led sales to IP‑owned, complex injectables with direct marketing authorization capability; recent EU registrations and Gufic Ireland’s first EU MA demonstrate intent to monetize high‑value molecules across Europe, LATAM and regulated geographies via licensing and tech‑transfer. Financially, Q3 FY26 revenue was INR231.1 crore with EBITDA INR37.1 crore (16.05% margin) and 9M FY26 revenue near INR688–692 crore; management cites one‑time receivable corrections to improve working capital, a consolidated debt profile around INR375 crore, and conservative guidance of at least 15% revenue growth for FY27.

Over the past 52 weeks, Gufic BioSciences Ltd has traded between a low of ₹267.50 and a high of ₹466.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gufic BioSciences Ltd has a market capitalization of approximately 4,368.31. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gufic BioSciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 59.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,368.31 Cr, Gufic BioSciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gufic BioSciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gufic BioSciences Ltd is 59.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.